Ichor’s business model centers around providing access to its patented TriGrid® electroporation devices to enhance the performance of partners’ nucleic acid therapeutics and vaccines by improving delivery to target tissues.


Ichor® has established several ongoing research and development collaborations and licensing agreements with leading research institutions such as Washington University, St. Louis, pharmaceutical companies including Janssen, as well as government agencies such as the National Institutes of Health and the US Department of Defense. Ichor is open to exploring additional partnerships that would utilize our expertise in in vivo nucleic acid delivery.  

Some current and past partners include:



Ichor continues to seek strategic partnerships to provide our enabling technology to collaborators interested in expanding their product pipeline in a number of disease indications, as well as partners with complementary resources and capabilities.

For further information regarding partnership opportunities at Ichor